T1	p 691 709	adult asthmatics .
T2	p 718 736	Sixty-six subjects
T3	i 6 44	Salmeterol plus fluticasone propionate
T4	i 52 93	fluticasone propionate plus montelukast :
T5	i 433 451	placebo-controlled
T6	i 504 601	salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M )
T7	o 605 687	sputum inflammatory markers , airway responsiveness , lung function , and symptoms
T8	o 818 1067	neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum . Additional outcomes included the change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .
T9	o 1121 1154	induced sputum inflammatory cells
T10	o 1190 1221	reduction in sputum eosinophils